A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.

Rui‐Hua Xu, Joy Yan, Dongsheng Zhang et al.|Journal of Clinical Oncology|2023

Cited by 32